BUFFALO GROVE, Ill. Akorn has signed a 10-year operating lease for a newly constructed product development facility located in Gurnee, Ill. This facility will represent the focal point for centralizing Akorn’s new product development activities.
This will consolidate development efforts that are presently managed in Decatur, Ill., and Somerset, N.J.
According to Shawn Silvestri, vice president of new product development, “This new, state-of-the art facility will position Akorn to compete on a global basis, enabling us to attract and recruit top-tier scientific talent. The facility will conform to the tenets of current good laboratory practices for research and development activities and will fulfill all requirements for the development of Akorn’s pipeline of NDA and ANDA filings for prescription drug products.”
The company’s over-the-counter products include AKWA tears in a solution and ointment as well as sodium chloride in ophthalmic ointment and solution.